HUMA News & Events

Humacyte announced the presentation of long-term data assessing the durability of Symvess in extremity arterial trauma patients at the Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society, VESS, in Olympic Valley, CA. The presentation, titled "Long-Term Outcomes of the Acellular Tissue Engineered Vessel in Extremity Arterial Trauma Repair: Results from the V005 Trial." In the V005 trial, Symvess maintained long-term structural integrity, exhibited low infection rates, and supported high rates of limb salvage in patients who were followed for up to 36 months. Among those treated in the V005 Phase 2/3 study were 54 patients who underwent extremity vascular repair with Symvess for whom treatment with autologous vein, the standard of care, was not feasible. Within this patient population, once early complications from the traumatic injuries resolved, the rates of conduit infection, limb salvage, and patient survival plateaued and remained relatively constant through the three years of follow-up. Symvess maintained an infection-free rate of 92.9% from months 3-36, with no infections after day 37 and only three conduit infections overall. Limb salvage rates were 87.3% at 12 months and 82.5% at 24 months, despite a severely injured trauma cohort.

Humacyte announced that the recently adopted FY 2026 U.S. Department of Defense Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries. The FY2026 National Defense Authorization Act, enacted in December 2025, stated in report language that DoD should "integrate FDA-approved breakthrough vascular repair technologies in traumatic extremity arterial injury repair, providing an off-the-shelf, biologically active vascular conduit when autologous vein harvesting is not feasible." Humacyte said: "In doing so, lawmakers demonstrated that they recognize and understand the need for human-derived bioengineered vessels to save life and limb on the battlefield. Humacyte is grateful to see Congress express even greater support for this medical innovation by designating appropriated funds to advance the goal of making this groundbreaking technology available to service members."

Humacyte announced the results of a five-year retrospective analysis of hospital charges, payer costs, and healthcare resource utilization in patients with extremity arterial injury. The average hospital charge for extremity arterial injury repair during initial hospitalization was $316,600 per patient, and amputations and infections increased the average hospital charge per patient by $492,986 and $589,921, respectively. Humacyte's Symvess has consistently demonstrated low rates of conduit infection and high rates of limb salvage in the treatment of extremity arterial injury. The company said, "Symvess offers an alternative to the high costs of complications from extremity arterial injury that occur when vein is not feasible for repair. As previously reported in JAMA Surgery, in clinical study Symvess's rate of infection was one-ninth that of synthetic graft historical controls, and Symvess's amputation rate was one-fifth that of historical controls."